225 related articles for article (PubMed ID: 32120995)
41. DNA methylation at enhancers identifies distinct breast cancer lineages.
Fleischer T; Tekpli X; Mathelier A; Wang S; Nebdal D; Dhakal HP; Sahlberg KK; Schlichting E; ; Børresen-Dale AL; Borgen E; Naume B; Eskeland R; Frigessi A; Tost J; Hurtado A; Kristensen VN
Nat Commun; 2017 Nov; 8(1):1379. PubMed ID: 29123100
[TBL] [Abstract][Full Text] [Related]
42. Kruppel-like factor 9 is a negative regulator of ligand-dependent estrogen receptor alpha signaling in Ishikawa endometrial adenocarcinoma cells.
Velarde MC; Zeng Z; McQuown JR; Simmen FA; Simmen RC
Mol Endocrinol; 2007 Dec; 21(12):2988-3001. PubMed ID: 17717078
[TBL] [Abstract][Full Text] [Related]
43. Chromatin Immunoprecipitation-Sequencing (ChIP-seq) for Mapping of Estrogen Receptor-Chromatin Interactions in Breast Cancer.
Holmes KA; Brown GD; Carroll JS
Methods Mol Biol; 2016; 1366():79-98. PubMed ID: 26585129
[TBL] [Abstract][Full Text] [Related]
44. Estrogen-dependent downregulation of hairy and enhancer of split homolog-1 gene expression in breast cancer cells is mediated via a 3' distal element.
Müller P; Merrell KW; Crofts JD; Rönnlund C; Lin CY; Gustafsson JA; Ström A
J Endocrinol; 2009 Mar; 200(3):311-9. PubMed ID: 19039095
[TBL] [Abstract][Full Text] [Related]
45. Regulation of estrogen-dependent transcription by the LIM cofactors CLIM and RLIM in breast cancer.
Johnsen SA; Güngör C; Prenzel T; Riethdorf S; Riethdorf L; Taniguchi-Ishigaki N; Rau T; Tursun B; Furlow JD; Sauter G; Scheffner M; Pantel K; Gannon F; Bach I
Cancer Res; 2009 Jan; 69(1):128-36. PubMed ID: 19117995
[TBL] [Abstract][Full Text] [Related]
46. Integrated high-throughput analysis identifies super enhancers associated with chemoresistance in SCLC.
Bao J; Li M; Liang S; Yang Y; Wu J; Zou Q; Fang S; Chen S; Guo L
BMC Med Genomics; 2019 May; 12(1):67. PubMed ID: 31118037
[TBL] [Abstract][Full Text] [Related]
47. Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer.
Salvati A; Melone V; Sellitto A; Rizzo F; Tarallo R; Nyman TA; Giurato G; Nassa G; Weisz A
Breast Cancer Res; 2022 Jul; 24(1):52. PubMed ID: 35850772
[TBL] [Abstract][Full Text] [Related]
48. Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor-alpha and the transcriptional repressor PLZF.
Buluwela L; Pike J; Mazhar D; Kamalati T; Hart SM; Al-Jehani R; Yahaya H; Patel N; Sarwar N; Heathcote DA; Schwickerath O; Phoenix F; Hill R; Aboagye E; Shousha S; Waxman J; Lemoine NR; Zelent A; Coombes RC; Ali S
Gene Ther; 2005 Mar; 12(5):452-60. PubMed ID: 15647773
[TBL] [Abstract][Full Text] [Related]
49. The estrogen-regulated transcription factor PITX1 coordinates gene-specific regulation by estrogen receptor-alpha in breast cancer cells.
Stender JD; Stossi F; Funk CC; Charn TH; Barnett DH; Katzenellenbogen BS
Mol Endocrinol; 2011 Oct; 25(10):1699-709. PubMed ID: 21868451
[TBL] [Abstract][Full Text] [Related]
50. Novel estrogen receptor-alpha binding sites and estradiol target genes identified by chromatin immunoprecipitation cloning in breast cancer.
Lin Z; Reierstad S; Huang CC; Bulun SE
Cancer Res; 2007 May; 67(10):5017-24. PubMed ID: 17510434
[TBL] [Abstract][Full Text] [Related]
51. Oestrogen receptor-co-factor-chromatin specificity in the transcriptional regulation of breast cancer.
Zwart W; Theodorou V; Kok M; Canisius S; Linn S; Carroll JS
EMBO J; 2011 Oct; 30(23):4764-76. PubMed ID: 22002538
[TBL] [Abstract][Full Text] [Related]
52. Chromatin Immunoprecipitation Assay to Identify Genomic Binding Sites of Regulatory Factors.
Wagner M; Jung J; Koslowski M; Türeci Ö; Tiwari VK; Sahin U
Methods Mol Biol; 2016; 1366():53-65. PubMed ID: 26585127
[TBL] [Abstract][Full Text] [Related]
53. Cooperation between the human estrogen receptor (ER) and MCF-7 cell-specific transcription factors elicits high activity of an estrogen-inducible enhancer from the trout ER gene promoter.
Lazennec G; Kern L; Salbert G; Saligaut D; Valotaire Y
Mol Endocrinol; 1996 Sep; 10(9):1116-26. PubMed ID: 8885246
[TBL] [Abstract][Full Text] [Related]
54. The estrogen receptor α is the key regulator of the bifunctional role of FoxO3a transcription factor in breast cancer motility and invasiveness.
Sisci D; Maris P; Cesario MG; Anselmo W; Coroniti R; Trombino GE; Romeo F; Ferraro A; Lanzino M; Aquila S; Maggiolini M; Mauro L; Morelli C; Andò S
Cell Cycle; 2013 Nov; 12(21):3405-20. PubMed ID: 24047697
[TBL] [Abstract][Full Text] [Related]
55. Loss of synergistic transcriptional feedback loops drives diverse B-cell cancers.
Andrews JM; Pyfrom SC; Schmidt JA; Koues OI; Kowalewski RA; Grams NR; Sun JJ; Berman LR; Duncavage EJ; Lee YS; Cashen AF; Oltz EM; Payton JE
EBioMedicine; 2021 Sep; 71():103559. PubMed ID: 34461601
[TBL] [Abstract][Full Text] [Related]
56. ELF5 modulates the estrogen receptor cistrome in breast cancer.
Piggin CL; Roden DL; Law AMK; Molloy MP; Krisp C; Swarbrick A; Naylor MJ; Kalyuga M; Kaplan W; Oakes SR; Gallego-Ortega D; Clark SJ; Carroll JS; Bartonicek N; Ormandy CJ
PLoS Genet; 2020 Jan; 16(1):e1008531. PubMed ID: 31895944
[TBL] [Abstract][Full Text] [Related]
57. COUP-TFII is a modulator of cell-type-specific genetic programs based on genomic localization maps.
Erdős E; Bálint BL
J Biotechnol; 2019 Aug; 301():11-17. PubMed ID: 31158411
[TBL] [Abstract][Full Text] [Related]
58. A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer.
Eeckhoute J; Carroll JS; Geistlinger TR; Torres-Arzayus MI; Brown M
Genes Dev; 2006 Sep; 20(18):2513-26. PubMed ID: 16980581
[TBL] [Abstract][Full Text] [Related]
59. Identification of activated enhancers and linked transcription factors in breast, prostate, and kidney tumors by tracing enhancer networks using epigenetic traits.
Rhie SK; Guo Y; Tak YG; Yao L; Shen H; Coetzee GA; Laird PW; Farnham PJ
Epigenetics Chromatin; 2016; 9():50. PubMed ID: 27833659
[TBL] [Abstract][Full Text] [Related]
60. Estrogen receptor 1 chromatin profiling in human breast tumors reveals high inter-patient heterogeneity with enrichment of risk SNPs and enhancer activity at most-conserved regions.
Joosten SEP; Gregoricchio S; Stelloo S; Yapıcı E; Huang CF; Yavuz K; Donaldson Collier M; Morova T; Altintaş UB; Kim Y; Canisius S; Moelans CB; van Diest PJ; Korkmaz G; Lack NA; Vermeulen M; Linn SC; Zwart W
Genome Res; 2024 May; 34(4):539-555. PubMed ID: 38719469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
